Skip to main content

Table 1 Methodological aspects of all included trials.

From: Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

Author Number of patients (exclusive controls) (1) Study methodology (2) Patiënt selection consequetive Golden standard (3) Clinical daignostic criteria clearly described? Minimal duration follow-up after scan (month) Radiotracer: pre- or postsynaptic or both Name of radiotracer (4) SPECT judged visually, template or drawn (5) Part of striatum judged (6) Cut-off point of 2 sd's taken by the authors? Drug stopped appropriate before SPECT? (7) SPECT judged blindly for clinical diagnoses?
Asenbaum '98 61 II, III - cc yes - pre beta m striatum 2sd yes yes
Benamer '00 185 II - cc yes - pre fpcit t striatum - yes yes
Booij '01 20 I - cf yes 24 pre fpcit t striatum 2sd - yes
Buck '95 23 II - cc yes - post ibf t striatum 2sd - -
Eerola '05 135 I yes cf yes 24 pre beta m striatum - yes -
Gerschlager '02 33 II - cc yes - pre beta m striatum - yes -
Haapaniemi '01 29 III - cf yes 24 pre beta t striatum - yes yes
Huang '01 34 III - cc yes - pre beta m putamen - yes -
Kim '02 31 II - cc yes - both beta/ibf t c-putamen - yes yes
Laere V '04 62 III yes . - . pre fp/tr t c-putamen - yes -
Lee '99 26 II - cc yes - pre ipt m striatum - yes -
Lokkegaard '02 72 I yes cf yes 14 pre beta t striatum - - yes
Lu '04 85 II - cc yes - pre trodat t c-putamen - - yes
Messa '98 18 II - cc yes - pre beta m c-pc - - -
Muller '98 24 III - dd yes - pre beta m striatum - yes yes
Oertel '93 67 II - fd - 3 post ibzm t striatum 2sd yes -
Oyanagi '02 13 II - cc yes - post ibf t striatum - yes -
Pirker '97 19 II - cc yes - post epide m striatum - yes -
Pirker '00 78 II - cc yes - pre beta m striatum - yes -
Pirker '02 51 II - cc yes - pre beta m striatum - yes yes
Plotkin '05 57 II yes cc yes - both fp/ibzm t putamen - yes yes
Rooyen v '93 21 II - cc - - posr ibzm m striatum - yes -
Schelvsky '93 44 II yes dd - - post ibzm t striatum - - -
Schwarz '98 65 I - fd yes 24 post ibzm t striatum 2sd yes yes
Schwarz '94 20 II - cc - - post ibzm t striatum - - -
Schwarz '00 28 III - dd yes - pre ipt t striatum - - -
Schwarz '97 55 I - fd - 24 post ibzm t striatum 2sd - yes
Schwarz '93 62 I yes fd - 4 post ibzm m striatum 2sd yes yes
Seppi '04 32 II yes cc yes - post ibzm m striatum 2sd yes -
Stoffers '05 70 I - cf yes 36 pre beta t c-pc 2sd yes -
Tatsch '91 42 II - cc - - post ibzm t striatum 2sd yes -
Vlaar '06 147 I yes cf yes 3 both fp/ibzm t putamen 2sd yes yes
  1. - means "no" or information not clearly mentioned by the authors
  2. 1) Number of patients of particular studied included in meta-analysis. Healthy controls and patients with diseases not relevant or inconclusive diagnosis for this study are not counted.
  3. 2) Study methodology
  4. I = patients with diagnostic uncertainty. Diagnostic accuracy of SPECT was determined with a surrogate gold standard
  5. II = cross sectional study of already diagnosed patient categories
  6. III = early PD vs. normalcy
  7. 3) cf = clinical criteria after follow-up
  8. cc = clinical criteria without follow-up
  9. dd = effect dopaminergic drugs or apomorphine test
  10. fd = clinical criteria after follow-up & effect dopaminergic drugs or apomorphine test
  11. 4) beta = Iodine-123-beta-CIT (beta-CIT), fpcit = Iodine-123-Ioflupane (FP-CIT), tr = Iodine-123-IPT and 99mCT-TRODAT-1.
  12. ibzm = 123I-iodobenzamide (IBZM), ibf = Iodine-123-Iodobenzofuran (IBF), epide = Iodine-123-epidepride.
  13. 5) t = region of interest determined with template
  14. m = region of interest manually encircled
  15. 6) bg = basale ganglia or striatum, put = putamen, cp = contralateral putamen, cpc = contralateral putamen/caudate ratio
  16. 7) Yes if: drugs with interference with radiotracer were stopped appropriately or if the subjects did not use dopaminergic drugs at the moment of the spect.
  17. (-) if this information was not given or if dopaminergic drugs seemed not to be stopped appropriately.